Home > Boards > US Listed > Biotechs >

Can-Fite BioPharma (CANF)

CANF RSS Feed
Add CANF Price Alert      Hide Sticky   Hide Intro
Moderator: midastouch017
Search This Board: 
Last Post: 5/16/2022 8:18:27 AM - Followers: 70 - Board type: Free - Posts Today: 0

Can-Fite BioPharma (TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and liver diseases.

The company platform technology utilizes the Gi protein associated A3 adenosine receptor (A3AR) as a therapeutic target. A3AR is highly expressed in inflammatory and cancer cells where low expression is found in normal cells, suggesting that the receptor could be a unique target for pharmacological intervention. The company compounds bind with nM affinity to the A3AR and initiate de-regulation of the NF-kB and the Wnt signal transduction pathways resulting in anti-inflammatory and anti-cancer effects

 
 

The company pipeline drugs are synthetic, highly specific agonists and allosteric modulators targeting the A3AR. All drugs are orally bioavailable with an excellent safety profile. Piclidenoson (CF101), Can-Fite`s lead drug candidate, is an oral drug that has been successfully tested in animal models and is currently in Phase III clinical studies for the treatment of Rheumatoid Arthritis (RA) and Psoriasis. All human clinical studies have demonstrated this drug to have an excellent safety profile. In two Phase II studies where Piclidenoson has been given as a standalone drug, data indicated that it acted as a disease modifying anti-inflammatory drug in RA patients. The Phase II and the Phase II/III clinical studies in Psoriasis showed clinical activity and safety of the drug. Namodenoson (CF102), Can-Fite`s second drug candidate, is an oral drug currently being developed for the treatment of Liver Diseases including hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH). CF602 an allosteric modulator at the A3AR which has shown proof of concept in pre-clinical pharmacology studies and is earmarked for the treatment of sexual dysfunction. Can-Fite has a wealth of clinical experience which includes over 1200 patients who have participated in clinical trials conducted by the company.

Can-Fite has licensed Piclidenoson for the treatment of autoimmune diseases to Cipher Pharmaceuticals in Canada, to Gebro Pharma GmbH in Spain, Switzerland & Austria,  for RA to Kwang Dong in Korea and to CMS for RA and Psoriasis in China, Taiwan, Hong Kong, Macao.

Can-Fite has licensed Namodenoson for the treatment of Liver Cancer and NASH to Chong Kun Dang Pharmaceut in Korea and to CMS in China.

Can-Fite is collaborating with leading researchers from the US NIH and the Leiden University in the Netherlands.

 

Israeli Office

10 Bareket Street
Kiryat Matalon
P.O. Box 7537
Petah-Tikva 49170
ISRAEL (Directions)

Tel: +972-3-9241114
Fax: +972-3-9249378

General email:
info@canfite.co.il

 

Investor Relations
(800)716-4880
info@canfite.co.il 


 

USA Office

255 Bear Hill Road, Suite 2200
Waltham
MA 02451
USA

Tel: +972-3-9241114
Fax: +972-3-9249378

http://www.canfite.com/

 

CANF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CANF News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 05/16/2022 03:16:40 AM
CANF News: Can-Fite Granted Key NASH Patent in Israel 05/16/2022 03:00:00 AM
CANF News: Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) 05/02/2022 03:10:14 AM
CANF News: Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted Cancer Immunotherapy Summit 05/02/2022 03:00:00 AM
CANF News: Can-Fite BioPharma (CANF) Receives a Buy from H.C. Wainwright 04/06/2022 02:25:28 AM
PostSubject
#1809  Sticky Note Can-Fite Issues Letter to Shareholders midastouch017 01/05/22 08:20:20 AM
#1864   Can-Fite Granted Key NASH Patent in Israel midastouch017 05/16/22 08:18:27 AM
#1863   Can-Fite’s CEO to Present Namodenoson’s Efficacy in Liver midastouch017 05/02/22 08:45:32 AM
#1862   Can-Fite BioPharma (CANF) Receives a Buy from H.C. Wainwright midastouch017 04/06/22 08:08:11 AM
#1861   Hi Spidey, midastouch017 04/06/22 05:40:54 AM
#1860   Hi Midas, Spideyboy 04/06/22 05:28:57 AM
#1859   CANF ended flat, not too far midastouch017 04/05/22 04:09:29 PM
#1858   Can-Fite reports positive data from preclinical trial of midastouch017 04/05/22 12:24:52 PM
#1857   Only thing I can think of is: 1. They murocman 04/05/22 09:14:19 AM
#1856   I do not understand the reason of midastouch017 04/05/22 08:24:54 AM
#1855   Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment midastouch017 04/05/22 08:19:59 AM
#1854   News out. This thing just seems not able The Stock Reader 04/05/22 08:18:17 AM
#1853   Based on the conference PR, it is not midastouch017 04/05/22 01:16:37 AM
#1852   Based on the conference PR, it is not murocman 04/04/22 04:02:37 PM
#1851   Hope for the best - prepare for the worst! midastouch017 04/04/22 02:32:22 PM
#1850   I had the chance to get out of The Stock Reader 04/04/22 02:04:30 PM
#1849   Hopefully some good news, or at midastouch017 04/04/22 01:45:20 PM
#1848   I would add more now if I had The Stock Reader 04/04/22 01:35:03 PM
#1847   If indeed the psoriasis results are midastouch017 04/04/22 12:11:06 PM
#1846   Me to probably before that even. lol The Stock Reader 04/04/22 11:58:10 AM
#1845   LOL, by $5.00 i'll be long gone! midastouch017 04/04/22 11:56:00 AM
#1844   Target price $9.00 moderate price is $7.00 so The Stock Reader 04/04/22 11:51:57 AM
#1843   I held on PLX, today is my reward: midastouch017 04/04/22 11:46:15 AM
#1842   We shall have the answer here in a The Stock Reader 04/04/22 11:39:37 AM
#1841   1.2700+0.0800 (+6.72%) midastouch017 04/04/22 11:07:24 AM
#1840   1.3000 +0.06 (+4.84%) midastouch017 04/01/22 08:22:00 AM
#1839   Can-Fite to Present at Dermatology Drug Development Summit midastouch017 03/28/22 08:24:41 AM
#1838   Dawson James Keeps Their Buy Rating on Can-Fite midastouch017 03/27/22 08:59:07 AM
#1837   Annual and Transition Report (foreign Private Issuer) (20-f) midastouch017 03/25/22 07:55:18 AM
#1836   1.1500+0.1300 (+12.75%) midastouch017 03/25/22 12:25:57 AM
#1835   Can-Fite Biopharma GAAP EPS of -$0.03, revenue of $0.85M midastouch017 03/24/22 09:46:06 AM
#1834   Can-Fite Reports 2021 Financial Results & Provides Clinical Update midastouch017 03/24/22 09:23:29 AM
#1833   Can-Fite stock rises 8% on notice of allowance midastouch017 03/14/22 09:10:50 AM
#1832   Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice midastouch017 03/14/22 09:07:08 AM
#1831   Can-Fite’s Findings in the Treatment of Liver Diseases midastouch017 03/11/22 08:17:09 AM
#1830   Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout midastouch017 03/08/22 01:56:19 PM
#1829   Can-Fite’s Phase III Psoriasis Study Data Expected Q2 2022 midastouch017 03/08/22 08:29:10 AM
#1828   https://www.marketscreener.com/quote/stock/CAN-FITE-BIOPHARMA-LTD-120961759/news midastouch017 03/01/22 01:48:15 PM
#1827   CANF: Beginning to Flex Its Muscles; Initiating with midastouch017 02/25/22 12:36:25 PM
#1826   Intracoastal Capital, Llc cuts stake in CANF / midastouch017 02/12/22 04:40:53 AM
#1825   Can-Fite begins enrollment in phase 2b trial of midastouch017 01/31/22 10:29:55 AM
#1824   should be the next step. good news. dshade 01/31/22 08:42:01 AM
#1823   Can Fite Announces First Patient Enrolled in Phase midastouch017 01/31/22 08:08:04 AM
#1822   support levels it appears dshade 01/20/22 12:52:02 PM
#1821   bidding dshade 01/20/22 12:51:47 PM
#1820   Can-Fite says Piclidenoson destroys pathological skin cells in vitro midastouch017 01/13/22 08:33:38 AM
#1819   Prior to Phase III Psoriasis Data Release Can midastouch017 01/13/22 08:27:39 AM
#1818   Can-Fite BioPharma (NYSEAMERICAN:CANF) Raised to Buy at Zacks midastouch017 01/13/22 01:55:20 AM
#1817   This is trading very tight - holding its danlevitan 01/11/22 02:13:31 PM
#1816   right better move on peterus 01/11/22 02:05:28 PM
#1815   Not matter what the share count is, seems Roadtojourney 01/11/22 11:32:37 AM
PostSubject
Consent Preferences